dehaze, a Munich-based healthtech startup, has raised €3.2 million in Seed funding led by YZR Capital and DN Capital, with participation from Angel Invest, Zoho, and Better Ventures.
The company is developing a foundational AI model focused on detecting chronic diseases earlier by analysing large-scale healthcare data.
What The Company Does
dehaze builds AI systems designed specifically for healthcare datasets, with an emphasis on identifying chronic disease risks before symptoms become severe or clinically obvious. Its platform uses causal AI to analyse patient information across multiple data sources and uncover patterns linked to future health outcomes.
The company works with healthcare payers and insurers, helping them identify high-risk individuals earlier, improve treatment pathways, and reduce avoidable long-term costs. By focusing on causal relationships rather than simple correlations, dehaze aims to provide more actionable insights for decision-makers.
Its platform is designed to process diverse healthcare datasets at scale, enabling earlier intervention strategies for conditions that often remain undetected until later stages.
Advertisement
Market Context / Industry Background
Chronic diseases remain the largest cost driver in global healthcare systems. Conditions such as cardiovascular disease, diabetes, respiratory illnesses, and other long-term disorders account for the majority of healthcare spending and a significant share of global mortality.
Despite the growing volume of digital health records, claims data, and patient information, much of this data remains underused in practice. Clinicians and healthcare organisations often rely on fragmented systems or limited manual review processes, meaning many preventable or manageable conditions are identified too late.
This creates a major opportunity for AI systems that can turn existing healthcare data into early warning signals and intervention pathways. Payers in particular have strong incentives to reduce downstream costs through prevention, making them an important early customer group for predictive health platforms.
As regulators and healthcare systems increasingly prioritise preventative care, startups focused on data-driven early detection are attracting growing investor interest.
At the same time, advances in machine learning and interoperability standards are making it easier to analyse diverse datasets across care settings. Solutions that can demonstrate measurable clinical outcomes, improved patient engagement, and lower treatment costs are expected to gain stronger traction among insurers, providers, and public health systems globally.
Founder Commentary
Co-founder and CEO Marius Klages said dehaze was built as a purpose-designed healthcare AI company rather than a generic software layer adapted to medicine.
“Our customers are global from day one, because the problem is global from day one,” he said.
He added that strong customer demand from payers supports the company’s view that early chronic disease detection will become an important new category over the coming years.
The comments reflect dehaze’s ambition to build infrastructure-level AI for preventative healthcare rather than a narrower clinical productivity tool.
Growth Plans / Use Of Funds
The new funding will be used to expand both technical and commercial teams while accelerating development of dehaze’s core platform.
Product priorities include strengthening the foundational AI model, adding next-best-action recommendation features, and improving traceability so customers can better understand how decisions and predictions are generated.
Commercially, the company is expected to scale relationships with healthcare payers and insurers in international markets, where cost containment and preventative care remain strategic priorities.
By combining causal AI with healthcare-specific data infrastructure, dehaze is positioning itself within a growing segment of AI-native preventative medicine platforms.
About dehaze
dehaze is a Munich-based healthtech startup focused on early chronic disease detection through artificial intelligence. The company develops healthcare-specific AI models that analyse large patient datasets to identify risk earlier, support intervention decisions, and reduce long-term healthcare costs. dehaze aims to help make healthcare more proactive, efficient, and prevention-led.
